Genmab price target raised to $46 from $44 at BTIG

BTIG analyst Kaveri Pohlman raised the firm’s price target on Genmab (GMAB) to $46 from $44 and keeps a Buy rating on the shares. The company’s Key Opinion Leader event indicates that its Amivantamab has the potential to replace AstraZeneca’s (AZN) Tagrisso in some areas of mEGFR NSCLC, if not all, the analyst tells investors in a research note. Amivantamab could receive approval based on Mariposa PFS results and could gain 50% peak market share since it’s a chemo-free regimen, despite physicians’ extensive experience with Tagrisso, the firm added.